ストックスクリーナーアプリを入手
0.4472
11.60%
0.0465
アフターアワーズ：
.48
0.0328
+7.33%
前日終値:
$0.4007
開ける：
$0.4382
24時間の取引高:
5.15M
Relative Volume:
2.91
時価総額：
$72.59M
収益：
$9.10M
当期純損益:
$-82.47M
株価収益率:
-0.771
EPS:
-0.58
ネットキャッシュフロー:
$-72.32M
1週間 パフォーマンス:
+40.58%
1か月 パフォーマンス:
+6.17%
6か月 パフォーマンス:
-46.45%
1年 パフォーマンス:
-36.99%
1日の値動き範囲:
$0.43
$0.4777
1週間の範囲:
$0.3251
$0.4777
52週間の値動き範囲:
$0.285
$1.07
Vaxart Inc Stock (VXRT) Company Profile
名前
Vaxart Inc
セクター
電話
(650) 550-3500
住所
170 HARBOR WAY, SUITE 300, SOUTH SAN FRANCISCO, CA
VXRT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VXRT
Vaxart Inc
|
0.4472 | 72.59M | 9.10M | -82.47M | -72.32M | -0.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.49 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.86 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
620.97 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
254.85 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.46 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Vaxart Inc Stock (VXRT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-15 | 開始されました | Oppenheimer | Outperform |
| 2021-12-29 | 再開されました | Jefferies | Buy |
| 2021-11-02 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-06-29 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2021-06-24 | 開始されました | Jefferies | Buy |
| 2021-06-11 | 開始されました | Piper Sandler | Overweight |
| 2020-08-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-13 | 開始されました | B. Riley FBR | Buy |
すべてを表示
Vaxart Inc (VXRT) 最新ニュース
Vaxart says it can resume next-gen Covid work, will screen participants for oral vaccine trial - Endpoints News
Layoff Tracker: Ono Cuts 83 Employees in Massachusetts - BioSpace
Federal government lifts hold on Peninsula biotech company's vaccine trial - The Business Journals
Vaxart resumes BARDA-funded trial activities - Investing.com
Vaccine biotechs say they’ve been told to stop next-gen Covid work under a Biden-era project - Endpoints News
Biota Pharmaceuticals to Present at Stifel 2015 Healthcare Conference - marketscreener.com
Vaxart to Present at World Vaccine Congress Washington 2025 on April 23 - GlobeNewswire
Revolutionary Oral Tablet Vaccines: Vaxart Reveals Latest Breakthrough Data at Major Congress - Stock Titan
Vaxartto Present at World Vaccine Congress Washington 2025 on April 23 - The Globe and Mail
Nasal Vaccines Market Top Companies StudyVaxart, Inc, FluGen Inc, Altimmune, Inc, Sinovac Biotech Ltd. - openPR.com
Proprietary - Vaxart Inc.
VXRT stock touches 52-week low at $0.31 amid market challenges - Investing.com Australia
VXRT stock touches 52-week low at $0.31 amid market challenges By Investing.com - Investing.com South Africa
RFK Jr. pauses $240 million contract for new ‘oral COVID vaccine’ - Todayville
VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates - MSN
Vaxart reports inducement grants under Nasdaq listing rule - TipRanks
Vaxart Stock Hits 52-Week Low at $0.45 Amid Market Challenges - Investing.com
Vaxart Stock Hits 52-Week Low at $0.45 Amid Market Challenges By Investing.com - Investing.com South Africa
Vaxart Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vaxart's Major Talent Investment: 659,500 Share Awards and Key Executive Hire Signals Growth - Stock Titan
B. Riley Cuts Price Target on Vaxart to $2 From $2.50, Keeps Buy Rating - MarketScreener
Vaxart, Inc. (NASDAQ:VXRT) Q4 2024 Earnings Call Transcript - Insider Monkey
Vaxart Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Oral - Vaxart Inc.
Sudden Trump administration order prompts Bay Area company to lay off staff - SFGATE
Bay Area biotech company lays off staff over sudden Trump admin order - SFGATE
Vaxart Inc to offer up to $50 mln of common stock -March 21, 2025 at 04:42 pm EDT - MarketScreener
RFK Jr. paused this Peninsula company's half-billion-dollar vaccine contract, then it cut jobs - The Business Journals
Vaxart Inc Reports Q4 EPS of -$0.12, Missing Estimates; Revenue at $19.5 Million, Below Expectations - GuruFocus
Vaxart Inc (VXRT) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic Adjustments ... - Yahoo Finance
Vaxart Inc (VXRT) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic Adjustments Amid Challenges - GuruFocus.com
Vaxart Reports 2024 Financial Results and Vaccine Progress - TipRanks
ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Vaxart, Inc. Investors of Important Deadline in Securities Class Action – VXRT - Business Wire
Earnings call transcript: Vaxart Q4 2024 misses EPS but beats revenue - Investing.com India
Vaxart Inc. (VXRT) reports earnings - Quartz
Vaxart Provides Business Update And Reports Full Year 2024 Financial Results -March 20, 2025 at 04:49 pm EDT - MarketScreener
Vaxart, Inc. SEC 10-K Report - TradingView
Vaxart Provides Business Update and Reports Full Year 2024 Financial Results - GlobeNewswire
Vaxart Quadruples Revenue to $28.7M as New Norovirus Vaccine Trial Launches - Stock Titan
FDA Mid-Month ID Food Recall Safety Updates - ContagionLive
Pipeline - Vaxart Inc.
Vaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20 - GlobeNewswire
Vaxart, Inc. to Host Conference Call for Business Update and Financial Results on March 20, 2025 - Nasdaq
Vaxart Inc (VXRT) 財務データ
収益
当期純利益
現金流量
EPS
0.19%
大文字化:
|
ボリューム (24 時間):